脑转移患者的死亡原因
基于纽约大学朗格尼健康中心2012至2021年接受立体定向放射外科治疗的脑转移患者数据,在439例有终末期数据的患者中,73.1%死于系统性疾病,10.3%死于中枢神经系统疾病,16.6%死于其他原因。死于中枢神经系统疾病者中,60%由颅内肿瘤负荷增加导致的全面衰退驱动。
要点
- 脑转移患者主要死于系统性疾病进展(73.1%),中枢神经系统原因占10.3%。
- 中枢神经系统死亡中,60%由颅内肿瘤负荷增加导致的全面衰退驱动。
- 死亡患者新发颅内肿瘤流入速率几乎为存活者的两倍(P<.001)。
核心结论
- 多数脑转移患者死于系统性疾病进展;因神经系统疾病死亡者,肿瘤动力学和死亡机制提示许多患者衰退的主要驱动因素可能是未控制的系统性疾病导致新肿瘤不断向中枢神经系统播散,而非局部生长控制失败。
研究设计与样本
- 利用NYUMets-Brain——最大的纵向、真实世界、开放性脑转移患者数据集,评估2012年至2021年在纽约大学朗格尼健康中心接受立体定向放射外科治疗的患者。
- 通过审查电子健康记录确定研究期间死亡患者的主要死亡原因,死因分类为互斥且 collectively exhaustive 的类别。
- 采用多水平模型评估颅内肿瘤动力学差异,包括体积和数量的变化。
主要发现
- 在439例有终末期数据的患者中,73.1%死于系统性疾病,10.3%死于中枢神经系统疾病,16.6%死于其他原因。
- 中枢神经系统死亡由急性颅内压升高(11%)、局灶性神经功能缺损(18%)、难治性癫痫发作(11%)和颅内肿瘤负荷增加驱动的全面衰退(60%)所致。
- 死亡患者新发颅内肿瘤的流入速率几乎为存活者的两倍(P<.001)。
- 每个颅内肿瘤的体积变化速率无差异(P=.95)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Advances in targeted therapies and wider application of stereotactic radiosurgery (SRS) have redefined outcomes of patients with brain metastases. Under modern treatment paradigms, there remains limited characterization of which aspects of disease drive demise and in what frequencies. This study aims to characterize the primary causes of terminal decline and evaluate differences in underlying intracranial tumor dynamics in patients with metastatic brain cancer. These fundamental details may help guide management, patient counseling, and research priorities. METHODS: Using NYUMets-Brain-the largest, longitudinal, real-world, open data set of patients with brain metastases-patients treated at New York University Langone Health between 2012 and 2021 with SRS were evaluated. A review of electronic health records allowed for the determination of a primary cause of death in patients who died during the study period. Causes were classified in mutually exclusive, but collectively exhaustive, categories. Multilevel models evaluated for differences in dynamics of intracranial tumors, including changes in volume and number. RESULTS: Of 439 patients with end-of-life data, 73.1% died secondary to systemic disease, 10.3% died secondary to central nervous system (CNS) disease, and 16.6% died because of other causes. CNS deaths were driven by acute increases in intracranial pressure (11%), development of focal neurological deficits (18%), treatment-resistant seizures (11%), and global decline driven by increased intracranial tumor burden (60%). Rate of influx of new intracranial tumors was almost twice as high in patients who died compared with those who survived ( P < .001), but there was no difference in rates of volume change per intracranial tumor ( P = .95). CONCLUSION: Most patients with brain metastases die secondary to systemic disease progression. For patients who die because of neurological disease, tumor dynamics and cause of death mechanisms indicate that the primary driver of decline for many may be unchecked systemic disease with unrelenting spread of new tumors to the CNS rather than failure of local growth control.
引用
- Schnurman Z, Mashiach E, Link KE, et al. Causes of Death in Patients With Brain Metastases. Neurosurgery. 2023. PMID: 37255296. doi:10.1227/neu.0000000000002542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。